NGEN

TD Cowen initiated coverage of Nervgen Pharma with a rating of Buy

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

EFFECT - NERVGEN PHARMA CORP. (0001751912) (Filer)

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

F-X - NERVGEN PHARMA CORP. (0001751912) (Subject)

F-10 - NERVGEN PHARMA CORP. (0001751912) (Filer)

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified assessment of treatment benefit. Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% (1/10) of placebo subjects (p=0.0001).These biomechanical gait findings join reported improvements in electrophysiological signaling, functional hand use, and quality of life, reflecting a consistent, multi-domain pattern of benefit with NVG-291 in the Phase 1b/2a CONNECT SCI study. VA

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the d

SUPPL - NERVGEN PHARMA CORP. (0001751912) (Filer)

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced that it has commenced an underwritten public offering of common shares and accompanying warrants to purchase common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase common shares and accompanying warrants to purchase co

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study initiation on track for mid-2026. Independent, blinded biomechanical gait analyses of the CONNECT SCI study designed to differentiate genuine neural recovery from compensatory movement remain ongoing, with results anticipated in 2Q 2026.Successfully listed on Nasdaq under the symbol 'NGEN' on January 8, 2026, and voluntarily delisted from the TSX Venture Exchange.Strengthened leadership team with three senior appointments to support late-stage clinical development and Nasdaq listing. VANCOUV

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

S-8 - NERVGEN PHARMA CORP. (0001751912) (Filer)

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)

H.C. Wainwright initiated coverage of Nervgen Pharma with a rating of Buy and set a new price target of $18.00

VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Keith Vendola, MD, MBA, as Chief Financial Officer (CFO), effective immediately. Dr. Vendola will lead the Company's financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives. "We are thrilled to welcome Keith, an accomplished leader with deep operational and f

VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. ("NervGen" or the "Company") (NASDAQ:NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company's executive leadership team, are scheduled to participate in the H.C. Wainwright "HCW@Home" series and the 2026 Bloom Burton & Co. Healthcare Investor Conference. H.C. Wainwright "HCW@Home" Series, April 15, 2026 Format:Fireside ChatDate:Wednesday, April 15thTime:1:00

Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint will be the change from baseline in GRASSP Quantitative Prehension at Week 12, a validated functional endpoint designed to capture improvement in fine-motor hand use, the highest priority domain in tetraplegia.Key secondary endpoints include Patient and Clinician Global Impression of Change (PGIC/CGIC), and blinded qualitative interviews designed to contextualize the clinical meaningfulness of NVG-291.RESTORE initiation remains on-track for mid-2026, with study initiation activities underway. VANCOUVER, British Columbia, April 07, 202

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses of the CONNECT SCI study in 2Q 2026, providing additional evidence with the potential to further support the systemic biological effect of NVG-291, differentiating genuine neural recovery from compensatory movement.Company expects to expand NVG-291 into complementary clinical indications, as informed by established preclinical efficacy, with prioritization expected to be announced by mid-2026. Successful N

40-F - NERVGEN PHARMA CORP. (0001751912) (Filer)

6-K - NERVGEN PHARMA CORP. (0001751912) (Filer)